Lantheus Holdings, Inc. (LNTH) ist ein börsennotiertes Unternehmen im Gesundheitswesen Sektor, tätig in der Drug Manufacturers - Specialty & Generic Branche. Der Hauptsitz des Unternehmens ist in Bedford, MA, United States. Der aktuelle CEO ist Mary Anne Heino.
LNTH hat IPO-Datum 2015-06-25, 808 Vollzeitbeschäftigte, gelistet an der NASDAQ Global Market, eine Marktkapitalisierung von $5.39B.
Lantheus Holdings, Inc. is a diagnostic and therapeutic company that develops, manufactures, and commercializes imaging and treatment products for heart disease, cancer, and other conditions worldwide. The company offers a comprehensive portfolio including DEFINITY for cardiac ultrasound enhancement, nuclear medicine generators and radiopharmaceuticals for diagnostic imaging, and therapeutic agents such as AZEDRA for radiotherapy and PYLARIFY for prostate cancer detection. Lantheus also markets RELISTOR for opioid-induced constipation and maintains a pipeline of investigational products including flurpiridaz F-18 for cardiac blood flow assessment and PSMA-targeted radiotherapeutics. The company serves hospitals, clinics, integrated delivery networks, and radio pharmacies through strategic partnerships with leading healthcare and pharmaceutical companies including GE Healthcare, Bayer, and Regeneron Pharmaceuticals. Founded in 1956 and headquartered in North Billerica, Massachusetts, Lantheus is a established player in nuclear medicine and molecular imaging.
